1. Market Research
  2. > Pharmaceutical Market Trends
  3. > China National Pharmaceutical Group Corporation - Product Pipeline Review - 2013

China National Pharmaceutical Group Corporation - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “China National Pharmaceutical Group Corporation - Product Pipeline Review - 2013” provides data on the China National Pharmaceutical Group Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, China National Pharmaceutical Group Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from China National Pharmaceutical Group Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- China National Pharmaceutical Group Corporation - Brief China National Pharmaceutical Group Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of China National Pharmaceutical Group Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of China National Pharmaceutical Group Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the China National Pharmaceutical Group Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate China National Pharmaceutical Group Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of China National Pharmaceutical Group Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the China National Pharmaceutical Group Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with China National Pharmaceutical Group Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of China National Pharmaceutical Group Corporation and identify potential opportunities in those areas.

Table Of Contents

China National Pharmaceutical Group Corporation - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
China National Pharmaceutical Group Corporation Snapshot 4
China National Pharmaceutical Group Corporation Overview 4
Key Information 4
Key Facts 4
China National Pharmaceutical Group Corporation - Research and Development Overview 5
Key Therapeutic Areas 5
China National Pharmaceutical Group Corporation - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
China National Pharmaceutical Group Corporation - Drug Profiles 9
JE Vaccine 9
Product Description 9
Mechanism of Action 9
RandD Progress 9
MMR-Varicella Vaccine 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
Tetravalent Meningococcal Conjugate Vaccine 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
China National Pharmaceutical Group Corporation - Pipeline Analysis 12
China National Pharmaceutical Group Corporation - Pipeline Products by Therapeutic Class 12
China National Pharmaceutical Group Corporation - Locations And Subsidiaries 13
Head Office 13
Other Locations and Subsidiaries 13
Appendix 15
Methodology 15
Coverage 15
Secondary Research 15
Primary Research 15
Expert Panel Validation 15
Contact Us 16
Disclaimer 16

List of Tables

China National Pharmaceutical Group Corporation, Key Information 4
China National Pharmaceutical Group Corporation, Key Facts 4
China National Pharmaceutical Group Corporation - Pipeline by Indication, 2013 6
China National Pharmaceutical Group Corporation - Pipeline by Stage of Development, 2013 7
China National Pharmaceutical Group Corporation - Monotherapy Products in Pipeline, 2013 8
China National Pharmaceutical Group Corporation - Pipeline By Therapeutic Class, 2013 12
China National Pharmaceutical Group Corporation, Subsidiaries 13

List of Figures

China National Pharmaceutical Group Corporation - Pipeline by Indication, 2013 6
China National Pharmaceutical Group Corporation - Pipeline by Stage of Development, 2013 7
China National Pharmaceutical Group Corporation - Monotherapy Products in Pipeline, 2013 8
China National Pharmaceutical Group Corporation - Pipeline By Therapeutic Class, 2013 12

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.